A Study of Efgartigimod in Patients With IgG4-Related Disease

Part of paid clinical trials in Palo Alto, California.

Sponsor: Stanford University
Study ID: NCT07025330
Phase: PHASE2
Status: Recruiting

Apply to this trial

Conditions

IgG4-related Disease

Eligibility Criteria

Sex: ALL
Age: 18 Years - 90 Years
Healthy Volunteers: Not accepted

Interventions

Efgartigimod — DRUG
efgartigimod 1000 mg subcutaneous injection given once weekly

Study Details

The goal of this clinical trial is to learn if efgartigimod can treat IgG4-related disease in adults. The main questions it aims to answer are: In patients with IgG4-related disease, does treatment with efgartigimod reduce the volume of the: * lacrimal gland(s) and/or * salivary gland(s) and/or * pancreas Participants will: * Receive efgartigimod once weekly for up to 12 weeks * Visit the clinic every one to six weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on efgartigimod

Key Dates

Start date: Nov 12, 2025
Status verified: Feb 2026
Primary completion: Mar 1, 2028
Completion: Jun 1, 2028

Study Design

Enrollment: 5 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: efgartigimod
Participants will be treated with efgartigimod 1000 mg subcutaneously once weekly for up to 12 weeks

Primary Outcome Measure

Change in volume on FDG-PET/MRI of lacrimal gland(s) and/or [ Time Frame: From Baseline to Week 12 ]

Central Contacts

Travis Deal
650-723-7416
[email protected]
Angie Aberia
[email protected]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Stanford University	Palo Alto	California	94304-2210	Travis Deal [email protected] 650-723-7416 Matthew C Baker, MD, MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Palo Alto, CA

By research site

Stanford University· Palo Alto, CA